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Protein glycosylationDisrupting protein glycosylation induces ER (endoplasmic reticulum) stress, resulting in the activation of UPR
(unfolded protein response) pathways. A key function of the UPR is to restore ER homeostasis, but prolonged
or unsolved ER stress can lead to apoptosis. MLL1 (Mixed Lineage Leukemia 1, also named ALL-1 or HRX), a his-
tone H3K4 methyltransferase in mammals, plays important roles in leukemogenesis, transcriptional regulation,
cell cycle and development. Here, we ﬁnd that Mll1 deﬁciency enhances UPR and apoptosis induced by the
glycosylation inhibitor TM (tunicamycin). The abnormal regulation of the UPR appears to be caused by a defect
in protein glycosylation. Furthermore,Mll1 directly binds to the promoters ofH6pd,Galnt12 andUgp2, which reg-
ulates H3K4 trimethylation and the subsequent expression of these genes. The knockdown of H6pd, Galnt12 or
Ugp2 enhances TM-induced apoptosis inMll1+/+MEF cells, whereas the ectopic expression of these proteins in-
hibits TM-induced apoptosis inMll1−/−MEF cells. Together, our data suggest that the maturation of glycopro-
teins in the ER is subject to regulation at the epigenetic level by a histone methyltransferase whose
abnormality can lead to cancer and developmental defects.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Almost all secreted and membrane-bound proteins are ﬁrst
co-translationally translocated into the lumen of the ER as unfolded
polypeptide chains. These nascent polypeptides are glycosylated by a
common N-linked oligosaccharide. Once properly folded, polypeptides
exit from the ER to the Golgi apparatus for extensive modiﬁcation.
Glycosylation is also a part of the quality-control machinery in the ER
that monitors the conformations of glycoproteins and determines
their destinations. The perturbations that disrupt the nucleotide-
sugar-precursor pool or glycosyltransferase activities result in glycosyl-
ation deﬁciency and induce the activation of intracellular signal trans-
duction pathways collectively named, the UPR [1–3].
Studies of the UPR mechanisms in mammalian cells have identiﬁed
three major ER-resident transmembrane proteins that act as stress
sensors to transmit the signals, including IRE1 (Inositol-Requiringenase; Galnt12, UDP-N-acetyl-
inyltransferase 12; Ugp2, UDP-
g Protein-1; ATF6, Activating
KR)-like ER Kinase; LAMP2,
dolichyl-phosphate (UDP-N-
ase 1 (GlcNAc-1-P transferase);
se
hanUniversity,Wuhan 430072,
yun@whu.edu.cn (L. Li).Protein-1), ATF6 (Activating Transcription Factor-6) and PERK (Protein
kinase RNA (PKR)-like ER Kinase) [2,4–8]. Both IRE1 and PERK are type I
transmembrane serine/threonine protein kinases. Once activated, these
kinases undergo oligomerization-dependent autophosphorylation and
initiate intracellular signal transduction [9,10]. Transcription factors
activated by all three ER stress transducers (i.e., XBP1(s), ATF4 and
p50ATF6) collaborate to activate the UPR target genes [6,11–16].
The initial goal of the UPR is to adapt cells to the altered proteostasis
in the ER by reducing misfolded proteins. However, if ER stress persists
and cannot be resolved, certain UPR effectors can switch roles from
survival promoters to apoptotic inducers. Prolonged ER stress promotes
apoptosis by activating CHOP, NOXA and JNK pathways [17–20]. ER
stress-induced cell death is thought to contribute to the pathogenesis
of a number of diseases, such as diabetes, renal diseases, neurodegener-
ative diseases, cancer and atherosclerosis [21].
MLL1 is one of the mammalian homologs of Saccharomyces cerevisiae
Set1 (SET domain-containing 1),whichwas characterized as a histoneH3
lysine 4 (H3K4) methyltransferase [22,23]. Trimethylation on histone
H3K4 at promoter regions is highly correlated with active transcription;
thus, the post-translational modiﬁcation is considered a key regulator
for gene transcription [24–26].
MLL1 was ﬁrst identiﬁed and linked to leukemia in 1991 [27]. Chro-
matin translocation resulting in the fusion of theMLL1 gene with up to
100 different genes leads to blockade of hematopoietic differentiation
and the induction of leukemia [28,29].
Though Mll1 deﬁciency leads to embryonic lethality, MEFs (mouse
embryonic ﬁbroblasts) derived fromMll1−/−mice grow normally [29].
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tively transcribed genes, where histone H3K4 trimethylation occurs [30,
31]. However, only approximately 5% of the actively transcribed genes
have reduced H3K4 trimethylation inMll1−/−MEF cells in comparison
with wild-type cells [32].
Studies on MLL1 over the past decades have suggested that MLL1 is
involved in many different important cellular pathways. It is reported
that MLL1 participates in cell cycle regulation [33–37] and that its
expression level is tightly regulated by the two E3 ligase complexes
SCFSKP2 and APCCDC20 [38,39]. MLL1 also regulates circadian gene tran-
scription [40]. We previously reported that MLL1 selectively regulates
the activation of NF-kappa B downstream genes stimulated by TNF-
alpha and LPS [41]. From our gene expression proﬁle data, we found
thatMll1 deﬁciency affects the transcription of genes in other cellular
pathways [41], indicating thatMll1 may regulatemore cellular process-
es in addition to the above-mentioned processes.
To study other biochemical pathways regulated by Mll1, we com-
pared the cytotoxicity of Mll1 knockout MEF cells to that of wild-type
cells exposed to different chemical inhibitors. We found that Mll1−/−
MEF cells are particularly sensitive to TM-induced cell death. Moreover,
these cells exhibit enhanced UPR activation. Mll1 deﬁciency enhances
the inhibition of protein glycosylation by TM in the ER. We further
showed that Mll1 regulates the expression of a set of glycosyltransfer-
ases and related enzymes, thereby affecting cellular sensitivity to TM.
2. Materials and methods
2.1. Cell lines and cell culture
Mll1+/+, Mll1−/− and F-MLL1 MEF cell lines were kindly provided
by Dr. Jay L. Hess (University of Pennsylvania). Cells were cultured
in complete DMEM (Dulbecco's modiﬁed Eagle'smedium) (Gibco) sup-
plemented with 10% fetal bovine serum (HyClone) and 1× penicillin/
streptomycin (HyClone).
2.2. Constructs, antibodies, siRNA and chemicals
The pRK-FLAG-H6pd plasmid was constructed by ligating PCR-
ampliﬁed mouse cDNA into the SalI and NotI sites of the pRK-FLAG
vector [42]. The pcDNA5-Galnt12 and pcDNA5-Ugp2 plasmids were
constructed by ligating PCR-ampliﬁed mouse cDNA into the restriction
digested BamHI and XhoI sites of the pcDNA5 vector (Invitrogen).
Antibodies used in this study include FLAG antibody (Sigma); actin
antibody (CWBIO); LAMP2, JNK and p-IRE1 (S724) antibodies (Epi-
tomics); IRE1, BiP, CHOP, p-PERK (T980), p-SAPK/JNK (T183/Y185) and
caspase-3 antibodies (Cell Signaling Technology); H3K4 trimethyla-
tion antibody (Millipore); WDR5 antibody (Upstate); ASH2L antibody
(BETHYL); H6PD, GALNT12 and UGP2 antibodies (Abcam).
The siRNAs against Mll1 (−GGACAAGAGTAGAGAGAGA−), H6pd
(−GCCAGAAGCTCATGGACAA−), Galnt12 (−CGGAAAGAAATACGCT
ATA−), Ugp2 (−GGATCTAACTGTTCAGCAA−), B4Galnt4 (−GGTTTG
GGTTCTATAAATA−), Glt8d2 (−CAACATGACTGAATGGAAA−), Wdr5
siRNA (−GAUGAAAGUGUGAGGAUAU−) and Ash2l siRNA (−AAGC
AAAGACCCAGAAGAA−) were synthesized by GenePharma.
TM (Calbiochem), TG (Calbiochem), A23187 (Abcam), BFA (Tocris
Bioscience) and 2-DG (Sigma) were stored as powders and dissolved
in dimethylsulfoxide (DMSO).
2.3. MTT assay and Western blotting analysis
Cell viability was performed by the MTT assay as previously de-
scribed [43]. Brieﬂy, cells were split at 1 × 103 per well in a 96-well
plate. After 24 h of culture, cells were treated with drugs for 48 h. MTT
(25 μg) was added to each well, and the cells were then incubated for
4 h at 37 °C. The medium with the formazan sediment was dissolved
in 50% DMF and 30% SDS (pH 4.7). The absorption was read at 570nm. Data represent the average ± SD of at least three independent
experiments performed in triplicate.
For the Western blotting assays, cells were harvested and then
lysed in 1× SDS loading buffer (60 mM Tris–HCl, pH 6.8, 2% SDS, 10%
glycerol, 5% 2-mercaptoethanol and 0.01% bromophenol blue). The
cell lysates were boiled at 95 °C for 5 min and subjected to sonication.
Proteins were resolved on an SDS-PAGE gel and transferred onto
NC polyvinylidene diﬂuoride membranes (Millipore). The blots were
blocked with 5% dry milk in TBS containing Tween 20 (0.1%) and incu-
bated overnight at 4 °C in blocking buffer containing primary antibod-
ies. The blots were then incubated with horseradish peroxidase-
conjugated secondary antibodies in blocking buffer and developed
using the ECL Western Blotting Detection Reagent was bought from
Millipore. Experiments were repeated at least three times. Data shown
are representative experiments.
2.4. RNA preparation and quantitative RT-PCR
qRT-PCRwas performed as previously described [41]. Total RNAwas
extracted using an RNA extraction kit (Yuanpinghao) according to the
manufacturer'smanual. For quantitative RT-PCR, cDNAwas synthesized
using a ﬁrst-strand cDNA synthesis kit (Toyobo). Real-time PCR
was performed using the SYBR green PCR Master mixture (Bio-Rad).
β-Actin was used to normalize the amount of each sample. The follow-
ing primers were used for qRT-PCR: H6pd F-agatgtaccgtgtggatcat,
R-ccttgcggttctgatctc; Ugp2 F-tgagtttgtcatggaagtca, R-gatttccaccagtct
cagtt; Galnt12 F-gtgctgaccttcctagactg, R-ggactccttctcgtggat; Dpagt1 F-
aggacctcaacaagctcag, R-gatgaagcagaagaggatga; BiP F-ctattcctgcgtcggtgt,
R-aggagtgaaggccacatac; Chop F-gacagagccagaataacagc, R-tgtggtggtgtatg
aagatg; Atf4 F-gctatggatgatggcttg, R-ttctccaacatccaatct; Gadd34 F-ggctc
agattgttcaaagc, R-ctttctcagcgaagtgtacc; Orp150 F-ccaaggaggctactctgtt,
R-tacagacatcacagccaatg; B4galnt4 F-cactctttcctcacactcgt, R-atccggagtcca
tagttctt; andGlt8d2 F-ttaccctctgctcaagacat, R-ttcttccggtagtccagata. The re-
sults shown are representative of three independent experiments
performed in triplicate. Data represent means ± SD.
2.5. Transient transfection
MEF cells were plated into 6-cm dishes for 14 h before transfection.
Transient transfectionswith plasmids or siRNAswere carried out inMEF
cells with Lipo2000 (Invitrogen). After transfection for 24 h, cells were
separated into 6-well or 96-well plates and treated with TM for the
indicated times and then analyzed by the MTT assay, Western blotting
or qRT PCR.
2.6. Glycoproteins isolation and detection
Cells were treated with or without TM, harvested and lysed in high-
salt lysis buffer (20 mMHepes pH 7.4, 10% glycerol, 0.35 M NaCl, 1 mM
MgCl2, 0.5% Triton X-100, 1 mM DTT) with proteinase inhibitors. Pro-
teinswere precipitatedwith saturated ammoniumsulfate and dissolved
in Concanavalin A Sepharose binding buffer (0.5 M NaCl, 2 mMMgCl2,
2 mM MnCl2 and 2 mM CaCl2). The glycoproteins were isolated with
Con A Sepharose 4B (Sigma) according to the manufacturer's instruc-
tions and resolved on an SDS-PAGE gel. The gel was stained using Pierce
Silver Stain Kit (Thermo). Experiments were repeated at least three
times. Data shown are representative experiments.
2.7. Alexa Fluor 594 Conjugate of wheat germ agglutinin (WGA) staining
MEF cells were plated on glass coverslips in 12-well tissue culture
plate. After 20 h incubation, cells were treated with or without TM
(50 ng/mL) for 24 h. After being washed with pre-warm HBSS (8 g/L
NaCl, 0.4 g/L KCl, 1 g/L glucose, 60 mg/L KH2PO4, 47.5 mg/L Na2HPO4,
0.35 g/L NaHCO3, pH 7.2), cells were incubated with 12.5 μg/mL Alexa
Fluor 594-WGA (Invitrogen) in HBSS for 45 min at 37 °C. Cells were
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were stained with DAPI for 5 min and mounted. Cells were examined
at ×100 magniﬁcation with a ﬂuorescence microscope. Experiments
were repeated at least three times. Data shown are representative
experiments.
2.8. ChIP assay
The ChIP assay was performed as previously described [41]. Brieﬂy,
cells were ﬁxed with 1% formaldehyde and quenched by glycine. They
were thenwashed three timeswith PBS and lysed in a buffer containing
50mM Tris–HCl, pH 8.0, 1% SDS and 5 mM EDTA. Cell lysates were sub-
jected to sonication to generate 400–600 bp DNA fragments before ex-
tensive centrifugation. Four volumes of ChIP dilution buffer containing
20 mM Tris–HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA and 1% Triton
X-100were added to the supernatant. The diluted lysates were then in-
cubated with protein G beads and antibodies at 4 °C overnight. The
beads were washed ﬁve times. DNA was eluted using the ChIP elution
buffer containing 0.1 M NaHCO3, 1% SDS, 30 mg/mL proteinase K at
65 °C overnight and extracted with a DNA puriﬁcation kit (Sangon,
China). The puriﬁed DNAwas analyzed by quantitative PCRwith BioRad
MyIQ. The primers used for ChIP were as follows: Hemoglobin 3′ UTR
F-ctttgggcatctagctttta, R-aatccttgcaagaaacaaaa; H6pd pro F-cgtttaactc
actcctctgg, R-gtgtagtctggaacctggaa; Galnt12 pro F-tcacgtaagttcaag
gaagg, R-atgagagagcagagagcttg; Ugp2 pro F-agttttccgtcttcaggatt, R-
tctttctcctccgatgttta; and Hoxa9 pro F-gggttaatttgtagcactgg, R-ccttg
gttatccttgaaaca. The results shown are representative of three indepen-
dent experiments performed in triplicate. Data represent means ± SD.
2.9. Xbp1 splicing assay
Xbp1 RNA was detected by standard RT-PCR using the following
primers: Xbp1 F-aaacagagtagcagcgcagactgc and R-tccttctgggtagacctctg
ggag. The PCR products were resolved on 3% agarose gels to separate
unspliced and spliced Xbp1mRNAs. The results shown are representa-
tive of three independent experiments.
3. Results
3.1. Mll1 deﬁciency increases cell sensitivity to TM-induced apoptosis
To investigate novel functions of MLL1, we performed a chemical
screen to evaluate the toxicity of various drugs to Mll1+/+ and
Mll1−/−MEF cells. The two cell lines were treated with different chem-
ical inhibitors for 48 h, and cell death was measured by the MTT (3-(4,
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, a tetrazole)
assay (data not shown). We observed that Mll1-deﬁcient cells were
more sensitive to TM-induced cell death at low concentrations (50–
100 ng/mL) (Fig. 1A).
Because TM induces ER stress by blocking protein glycosylation and
maturation in the ER, we speculated that Mll1 may regulate ER stress
signaling. We treated cells with other ER stress inducers, including TG
(thapsigargin, an inhibitor of sarcoplasmic or endoplasmic reticulum
Ca2+ ATPases [SERCAs]), A23187 (a calcium ionophore) and BFA
(Brefeldin A, an inhibitor of ER–Golgi transport). To our surprise, the
two cell lines showed no difference in their sensitivity to cell death in-
duced by TG and A23187 and only a small difference by BFA treatment
(Fig. 1B–D).
Consistent with the MTT results, phase-contrast microscopy revealed
that TM-treated Mll1−/−MEF cells exhibited features of cell apoptosis
such as cell pyknosis and shrinkage, whereas Mll1+/+ MEF cells looked
normal (Fig. 1E). Immunoblotting assays also showed that TM (50 ng/
mL) induced the cleavage of caspase-3 inMll1−/− cells after 48 h of treat-
ment (Fig. 1F). To exclude the possibility that the difference in TM sensi-
tivity might derive from the two independently developed cell lines, we
transiently transfected small interfering RNA (siRNA) targetingMll1 intowild-type MEF cells, which resulted in the down-regulation of Mll1
mRNA by ~80% (Fig. 1G, right panel).Mll1 knockdownMEF cells showed
a strong reduction in cell viability after TM treatment, whereas TG treat-
ment showed no difference (Fig. 1G). To further conﬁrm that the in-
creased sensitivity to TM was a consequence of Mll1 deﬁciency, we
performed the MTT assay using a cell line in which a Flag-tagged wild-
type MLL1 had been integrated into the genome ofMll1−/− cells (desig-
nated F-MLL1) [41]. In comparison withMll1−/− cells, the cell viability
of the F-MLL1 cell line was partially rescued by TM treatment (Fig. 1H).
Thus,Mll1 deﬁciency increases cell sensitivity to TM-induced apoptosis.
3.2. Mll1 deﬁciency enhances the TM-induced UPR and apoptosis
TM induces ER stress and activates the UPR in mammalian cells. The
UPR activation causes oligomerization-dependent autophosphorylation
of IRE1 and PERK to activate downstreamgenes. Therefore, we analyzed
the phosphorylation of Ire1 and Perk in both cell lines under TM treat-
ment. Compared with wild-type cells, phosphorylated Ire1 and Perk in-
creased more signiﬁcantly in Mll1−/− cells after treatment with TM
(50 ng/mL) for 24 h and persisted to 48 h when cells became apoptotic
(Fig. 2A). The activation of IRE1 catalyzes XBP1 (X-box transcription
factor 1) mRNA to generate a spliced form, XBP1(s), which encodes a
transcription activator [11]. Consistent with the Ire1 phosphorylation
results, we observed Xbp1 splicing in Mll1−/− cells following TM
(50 ng/mL) treatment but not inMll1+/+ cells (Fig. 2B, lane 2 versus 5).
However, the spliced form of Xbp1 appeared in both cell lines under TM
(500 ng/mL) treatment (Fig. 2B, lane 3 versus 6).
Next, we analyzed the expression of known UPR downstream
genes, such as BiP, Chop, Gadd34, Atf4 and Orp150, by quantitative RT-
PCR (qRT-PCR) following TM treatment. The data showed that TM
(50 ng/mL) treatment increased the mRNA levels of these genes in
both cell lines but to a much higher level in Mll1−/− cells (Fig. 2C).
Thus, the Mll1-deﬁcient cells are more prone to activate the UPR
pathways. This conclusion was further supported by the observa-
tion that the protein levels of BiP and Chop increased signiﬁcantly in
Mll1−/− cells following TM treatment (Fig. 2D).
Prolonged ER stress triggers apoptosis by activating CHOP- and JNK-
dependent pathways [17]. As shown in Fig. 2D, the expression of Chop
dramatically increased inMll1−/−MEF cells after TM treatment for 24
h and lasted up to 48 h. Meanwhile, phosphorylated JNK was strong
and persistent in Mll1−/− cells, but it was weak in Mll1+/+ cells. Fur-
thermore, activated caspase-3 was detected inMll1−/− cells but not in
wild-type cells. The data indicate that low concentrations of TM induce
a moderate UPR in wild-type cells and that the cells do not enter apo-
ptosis at the time points analyzed. By contrast, Mll1 knockout cells
have much stronger reactions to TM and are more sensitive to TM-
induced apoptosis. We conclude that Mll1 is required to maintain pro-
tein homeostasis in the ER.
3.3. Mll1 deﬁciency enhances the inhibition of protein glycosylation by TM
Because TM is an inhibitor of proteinN-linked glycosylation andMll1
deﬁciency results in an increased and sustained activation of the UPR
after TM (but not TG) treatment, we wondered whether Mll1 plays a
role in regulating protein glycosylation.We used twomethods to detect
glycoproteins, one is using Con A-Sepharose to purify glycoproteins, and
the other one is using Alexa Fluor 594 Conjugate ofWGA to stain glyco-
sylated proteins in the cells. The Con A lectin recognizes α-linked man-
nose and terminal glucose residues, while the WGA lectin selectively
binds to GlcNAc (N-Acetyl glucosamine) groups and to sialic acid. We
observed that there was a signiﬁcant decrease of Con A-bound glyco-
proteins in Mll1−/− MEF cells with TM treatment compared with
Mll1+/+ cells, which was rescued in F-MLL1 cells (Fig. 3A). When the
three cell lines were stained with Alexa Fluor 594 Conjugate of WGA,
we also observed that the red ﬂuorescence signal (WGA-bound mole-
cules) became weak only in TM-treated Mll1−/− MEF cells (Fig. 3B).
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Fig. 1.Mll1−/−MEF cells are more sensitive to TM-induced apoptosis than wild-type cells. (A–D) Dose-dependent reduction in cell viability ofMll1+/+ andMll1−/−MEF cells after treat-
mentwith TM, TG, A23187 and Brefeldin A. Cell viabilitywasmeasured by theMTT assay after 48h of treatment as indicated. (E) Phase contrastmicroscopyof control samples and samples
treatedwith TM for 48 h at 50 and 100 ng/mL, respectively, inMll1+/+ andMll1−/−MEF cells (×100). (F)Whole cell lysates ofMll1+/+ andMll1−/−MEF cells treatedwith 50 ng/mL TM
for the indicated times were analyzed by immunoblotting with anti-caspase-3 and anti-actin. *Nonspeciﬁc bands. Results shown are representative of at least three independent
experiments. (G)Mll1 knockdown inMll1+/+ cells promotes cell apoptosis upon TM treatment but not TG treatment. Cell viability was measured by the MTT assay. The knockdown
efﬁciency was measured by qRT-PCR. **P b 0.01 (t test). (H) F-MLL1 MEF cells rescue cell viability under TM treatment compared withMll1−/− cells. Cell viability was measured by the
MTT assay.
2595X. Wang et al. / Biochimica et Biophysica Acta 1843 (2014) 2592–2602Furthermore, we used a well-demonstrated glycosylated protein
LAMP2 (Lysosomal Associated Membrane Protein 2) as an example to
examine if Mll1 affects its glycosylation. LAMP2, also known as
CD107b (Cluster of Differentiation 107b), is a highly glycosylated lyso-
some membrane protein that is synthesized and matured in the ER
and Golgi. LAMP2 contains a polypeptide core of approx. 40 kDa. How-
ever, after glycosylation, the molecular mass of the LAMP2 is approx.
110 kDa [44,45]. As shown in Fig. 3C, glycosylated Lamp2 decreased
markedly and unglycosylated Lamp2 increased in Mll1−/− cells
after TM (50 ng/mL) treatment for 24 h, compared with that in control
Mll1−/− cells (Fig. 3C, lane 3 versus 4). By contrast, therewas noobvious
difference between wild-type cells treated with or without TM (Fig. 3C,
lane 1 versus 2). F-MLL1 cells treated with TM partially rescued the
phenotype of Mll1−/− (Fig. 3C, lane 4 versus 6). Concomitantly, weobserved that unglycosylated Lamp2 already appeared when Mll1−/−
MEF cells were treated with 50 ng/mL TM for 8 h (Fig. 3D, lane 6),
whereas unglycosylated Lamp2 was detected in wild-type cells under
500 ng/mL TM treatment for 24 h (Fig. 3D, lane 4). To exclude the pos-
sibility thatMll1may regulate the level of Lamp2 by controlling its tran-
scription, we measured themRNA level of Lamp2 by RT-PCR. There was
no difference among the three cell lines regardless of TM treatment
(Fig. 3E). As expected, the calcium pump inhibitor TG did not reduce
glycosylated Lamp2 after treatment for 24 h (data not shown). These
results strongly indicate that the inhibition of protein glycosylation by
TM treatment is enhanced byMll1 deﬁciency. Given that glycosylation
is required for the folding andmaturation of many ER proteins, reduced
glycosylation efﬁciency inMll1−/−MEF cells provides a plausible expla-
nation for the increased sensitivity to TM-induced UPR and apoptosis.
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binding and histone H3K4 methylation
Because Mll1 is an epigenetic regulator for gene transcription,
we speculated that Mll1 deﬁciency could lead to down-regulate the
transcription of glycosylation-related enzymes. From Mll1+/+ and
Mll1−/− MEF cell gene expression proﬁles published previously
[41], we chose several glycosylation-related candidates and per-
formed qRT-PCR to verify their mRNA levels (data not shown). We
found that the mRNA levels and protein levels of three genes de-
creased dramatically in Mll1−/− cells, including H6pd (hexose-6-
phosphate dehydrogenase), Galnt12 (UDP-N-acetyl-alpha-D-galac-
tosamine:polypeptide N-acetylgalactosaminyltransferase 12) andUgp2 (UDP-glucose pyrophosphorylase 2) (Fig. 4A–C, and E).
This phenotype was not dependent on TM treatment. Because the
expression of FLAG-tagged MLL1 in Mll1−/− cells rescued the
mRNA levels and protein levels of these genes, the effect on gene ex-
pression is clearly due to Mll1 deﬁciency (Fig. 4A–C, and E). By
comparison, the mRNA level of Dpagt1 (dolichyl-phosphate (UDP-N-
acetylglucosamine) N-acetylglucosaminephosphotransferase 1
(GlcNAc-1-P transferase)), which catalyzes the ﬁrst step in the
dolichol-linked oligosaccharide pathway for glycoprotein biosynthesis
and is inhibited by TM [46–48], did not change (Fig. 4D).
We next asked whether Mll1 regulates the expression of H6pd,
Galnt12 and Ugp2 by directly binding to their promoters. To explore
this question, we ﬁrst performed ChIP assays in F-MLL1 cell lines and
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(Fig. 4E). Mll1 is one of the H3K4 methyltransferases in mammalian
cells, where it trimethylates H3K4 to promote gene expression [30,31].
Thus, wewonderedwhetherMll1mediates histone H3K4 trimethylation
on the promoters of these genes. A ChIP assay using an antibody speciﬁc
to H3K4 trimethylation showed that H3K4 trimethylation on the pro-
moters of the genes decreased dramatically in Mll1−/− MEF cells
(Fig. 4F). These results indicate that Mll1 binds the promoters of H6pd,
Galnt12 and Ugp2 and is required for the trimethylation of H3K4 at the
loci required to promote their expression.
3.5. Knockdown of H6pd, Galnt12 or Ugp2 in Mll1+/+ MEF cells increases
sensitivity to the TM-induced UPR and apoptosis
If the increased sensitivity to TM-induced cell death inMll1−/− cells
is due to reduced glycosylation capacity, one would expect to see asimilar phenotype in cells expressing reduced glycosylation-related
genes. To test this idea, we transfected siRNAs targeting the above
three genes in Mll1+/+ cells and performed MTT assays. The data
showed that the knockdown of H6pd, Galnt12 or Ugp2 increased sensi-
tivity to TM inMll1+/+ cells (Fig. 5A). Knockdown efﬁciency was con-
ﬁrmed by qRT-PCR and Western blotting (Fig. 5B). Like Mll1−/− cells,
the expression of BiP and Chop increased under TM treatment in H6pd,
Galnt12, or Ugp2 knockdown cells compared with wide-type MEF cells
transfected with a control siRNA, suggesting that these cells are also
more prone to UPR activation by TM (Fig. 5C).
3.6. Exogenous expression of H6pd, galnt12 and Ugp2 inMll1−/−MEF cells
rescues cell viability under TM treatment
We next conducted an experiment to test whether increasing the
expression of H6pd, Galnt12 or Ugp2 inMll1−/−MEF cells can protect
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full-length cDNA into mammalian expression vectors and transfected
them either individually or all together intoMll1−/−MEF cells. In com-
parisonwithMll1−/−MEF cells transfectedwith an empty vector, cell vi-
ability under TM treatmentwas signiﬁcantly increasedwhen exogenous
H6pd, Galnt12 orUgp2was expressed individually. Furthermore,we ob-
served that the co-expression of the three genes indeed rescued the cell
viability much better than the expression of the individual genes
(Fig. 6A). Fig. 6B shows the expression of these genes in transfected
cells. Additionally,Mll1−/−MEF cells exogenously expressing the three
genes either individually or all together had reduced BiP and Chop
mRNA induction under TM treatment compared with the control, indi-
cating less UPR induction (Fig. 6C). We also found that glycosylated
Lamp2 increased in Mll1−/− cells co-transfected with H6pd, Galnt12and Ugp2 (Fig. 6D). The exogenous expression of the three genes did
not affect the transcription of Lamp2. The data indicate that Mll1 regu-
lates the expression of H6pd, Galnt12 and Ugp2 to maintain glycopro-
tein homeostasis in the ER.
Taken together, our observations show that Mll1 regulates protein
glycosylation and affects TM-induced UPR and apoptosis via regulating
the transcription of glycosylation-related genes.
4. Discussion
In this study, we discover a previously unknown role for histone
H3K4 methyltransferase Mll1 in the regulation of protein glycosylation
and ER function. We show thatMll1 deﬁciency results in stronger UPR
activation and cell apoptosis under low concentrations of TM treatment,
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disturbed protein homeostasis caused by low doses of TM but that
Mll1−/− cells lose this capability (Figs. 1 and 2).
Mll1−/−MEF cells only exhibit higher sensitivity to TM but not TG or
A23187. TM speciﬁcally inhibits the dolichol pyrophosphate-mediated
glycosylation of asparagine residues in nascent glycoproteins, resulting
in the UPR activation in mammalian cells [48]. Using multiple ap-
proaches to detect glycoproteins, we prove that the inhibition of protein
glycosylation by TM is enhanced in Mll1−/−MEF cells, indicating that
Mll1 plays a regulatory function in protein glycosylation (Fig. 3). Inter-
estingly, glycosylated Lamp2 is reduced in Mll1−/− cells compared
withMll1+/+ cells without TM treatment (Figs. 3C, lane 1 versus 3; 3D,
lane 1 versus 5). On the other hand, without TM treatment, there is no
obvious difference of Con A-bound glycoproteins betweenMll1+/+ and
Mll1−/− cells (Fig. 3A). This suggests thatMll1 deﬁciency impairs the gly-
cosylation of speciﬁc proteins, such as Lamp2, but not global proteinglycosylation. However, the global level of protein glycosylation de-
creases dramatically whenMll1−/− cells were treated with low concen-
tration of TM.
We also use the other two glycosylation inhibitors BFA and 2-deoxy-
D-glucose (2-DG) to treat cells and ﬁnd thatMll1−/− cells are also more
sensitive to these two glycosylation inhibitors (Figs. 1D and S1). Howev-
er, compared with TM, BFA and 2-DG only generate minor differences
between Mll1+/+ and Mll1−/− cells. The main reason is probably
that the three inhibitors function at different stages of protein glyco-
sylation. In the ER, the glycan G3M9Gn2 (glucose3mannose9 N-
acetylglucosamine2) is transferred from G3M9Gn2-P-P-dolichol, a LLO
(lipid-linked oligosaccharide), to asparagine residues of nascent poly-
peptides. Properly folded glycoproteins exit from the ER to the Golgi ap-
paratus for extensivemodiﬁcation. Perturbation of LLO synthesis results
in aberrant N-linked glycosylation. The target of TM is Dpagt1, which
catalyzes the transfer of GlcNAc-1-P from UDP-GlcNAc to dolichol-P to
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charide pathway for glycoprotein biosynthesis). Therefore, TM inhibits
protein glycosylation at the very early stage. BFA blocks protein trans-
port from the endoplasmic reticulum to the Golgi apparatus. Thus, BFA
functions at a later stage of protein glycosylation. 2-DG is a glucosemol-
ecule which has the 2-hydroxyl group replaced by hydrogen. As an an-
alog of glucose, 2-DG is converted to the GDP-deoxyglucose that
prevents the formation of the LLOs and N-linked glycosylation
[49–51]. Under treatment with 2-DG, the pattern of oligosaccharides
is altered and the molecular weight of oligosaccharides decreases [49].
BecauseMLL1 performs functions inmany cellular processes by reg-
ulating gene expression, we surmise that Mll1 regulates the expression
of enzymes involved in glycometabolism or protein glycosylation.
We pick 12 glycosylation-related genes that may have differential ex-
pression betweenMll1+/+ and Mll1−/− cells from our published gene
expression proﬁle data. Then we perform qRT-PCR to verify their ex-
pressions. We observe that the expressions of ﬁve genes were signiﬁ-
cantly down-regulated inMll1−/− cells, including H6pd, Galnt12, Ugp2,B4galnt4 (beta-1, 4-N-acetyl-galactosaminyl transferase 4) and Glt8d2
(glycosyltransferase 8 domain containing 2) (Figs. 4A–C; S2, A). However,
only knockdown of H6pd, Galnt12 and Ugp2 inMll1+/+ cells promoted
TM-induced cell death (Figs. 5A; S2, B). Therefore, we focus on the
study of H6pd, Galnt12 and Ugp2. Next, we observed that Mll1 binds
to the promoters of H6pd, Galnt12 and Ugp2, catalyzes H3K4
trimethylation, and regulates the expression of these genes (Fig. 4). Be-
cause the enzymatic activity ofMLL1 is dependent on other core compo-
nents, we show that knockdown of Ash2l andWdr5 (two components of
Mll1 complex) individually promotes TM-induced cell death, and co-
knockdown of the two genes causes a much stronger phenotype
(Fig. S3).
H6PD, which is located in the ER, is a glucose-6-phosphate dehydro-
genase that catalyzes the ﬁrst two reactions of the pentose-phosphate
pathway, converting glucose-6-phosphate to 6-phosphogluconate and
generating NADPH [52]. The deletion of H6pd in mice induces the UPR
and skeletal myopathy [53]. Galnt12 is a member of a Golgi-resident
family of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase
2601X. Wang et al. / Biochimica et Biophysica Acta 1843 (2014) 2592–2602and catalyzes the transfer of N-acetylgalactosamine (GalNAc) from
UDP-GalNAc to a serine or threonine residue on a protein in the initial
step of O-linked protein glycosylation. Galnt12 plays an important
role in mucin-type oligosaccharide biosynthesis in digestive organs
[54,55]. Ugp2 belongs to an enzyme family that catalyzes the transfer
of a glucose moiety from glucose-1-phosphate to MgUTP, forming
UDP-glucose and MgPPi [56,57]. Overexpression of the three genes
indeed partially rescues the cell viability of Mll1−/− MEF cells under
TM treatment and attenuates UPR induction by TM. Meanwhile, co-
transfecting the three genes together increased glycosylated Lamp2
(Fig. 6D). However, the detailed mechanism by which the three genes
regulate protein glycosylation requires further investigation.
Taken together, our data show that Mll1 impacts protein glycosyla-
tion and TM-induced ER stress and apoptosis through regulating the ex-
pression of several glycosyltransferases and related enzymes. However,
because our previous research showed that a fraction of MLL1 exists in
the cytosol, we could not eliminate other possible mechanisms where
MLL1 may perform functions in the cytosol. Because leukemia patients
bearing a genetic rearrangement in the MLL1 gene only contain one
copy ofwild-typeMLL1, the expression ofMLL1 target genes is expected
to change in these patients. Thus, it would be interesting to investigate
whether leukemia cells are more sensitive to drugs such as TM. Our
discovery raises a new therapeutic possibility for the treatment of
leukemia.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.06.013.
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